Danja Sarink to Cohort Studies
This is a "connection" page, showing publications Danja Sarink has written about Cohort Studies.
Connection Strength
0.572
-
Sarink D, Franke AA, White KK, Wu AH, Cheng I, Quon B, Le Marchand L, Wilkens LR, Yu H, Merritt MA. BPA, Parabens, and Phthalates in Relation to Endometrial Cancer Risk: A Case-Control Study Nested in the Multiethnic Cohort. Environ Health Perspect. 2021 05; 129(5):57702.
Score: 0.144
-
Sarink D, Wilkens LR, White KK, Le Marchand L, Wu AH, Setiawan VW, Park SL, Park SY, Killeen JL, Merritt MA. Racial/ethnic differences in anthropometric and hormone-related factors and endometrial cancer risk: the Multiethnic Cohort Study. Br J Cancer. 2021 05; 124(10):1724-1733.
Score: 0.143
-
Sarink D, Wu AH, Le Marchand L, White KK, Park SY, Setiawan VW, Hernandez BY, Wilkens LR, Merritt MA. Racial/Ethnic Differences in Ovarian Cancer Risk: Results from the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev. 2020 10; 29(10):2019-2025.
Score: 0.137
-
Sarink D, Schock H, Johnson T, Chang-Claude J, Overvad K, Olsen A, Tj?nneland A, Arveux P, Fournier A, Kvaskoff M, Boeing H, Karakatsani A, Trichopoulou A, La Vecchia C, Masala G, Agnoli C, Panico S, Tumino R, Sacerdote C, van Gils CH, Peeters PHM, Weiderpass E, Agudo A, Rodr?guez-Barranco M, Huerta JM, Ardanaz E, Gil L, Kaw KT, Schmidt JA, Dossus L, His M, Aune D, Riboli E, Kaaks R, Fortner RT. Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort. BMC Cancer. 2018 Oct 22; 18(1):1010.
Score: 0.121
-
Fortner RT, Sarink D, Schock H, Johnson T, Tj?nneland A, Olsen A, Overvad K, Affret A, His M, Boutron-Ruault MC, Boeing H, Trichopoulou A, Naska A, Orfanos P, Palli D, Sieri S, Mattiello A, Tumino R, Ricceri F, Bueno-de-Mesquita HB, Peeters PH, Van Gils CH, Weiderpass E, Lund E, Quir?s JR, Agudo A, S?nchez MJ, Chirlaque MD, Ardanaz E, Dorronsoro M, Key T, Khaw KT, Rinaldi S, Dossus L, Gunter M, Merritt MA, Riboli E, Kaaks R. Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort. BMC Med. 2017 02 08; 15(1):26.
Score: 0.027